We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Becton Dickinson (BDX) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Becton Dickinson (BDX - Free Report) is expected to reveal quarterly earnings of $3.77 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $5.35 billion, representing an increase of 5.2% year over year.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Becton Dickinson metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- BD Medical' should come in at $2.73 billion. The estimate indicates a change of +7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional' of $1.25 billion. The estimate points to a change of +51.7% from the year-ago quarter.
Analysts forecast 'Revenues- BD Life Sciences' to reach $1.37 billion. The estimate suggests a change of +2.7% year over year.
The average prediction of analysts places 'Revenues- BD Life Sciences- Biosciences' at $408.06 million. The estimate indicates a year-over-year change of +0.8%.
Based on the collective assessment of analysts, 'Revenues- BD Medical- Medication Management Solutions- International' should arrive at $191.71 million. The estimate suggests a change of -1.2% year over year.
Analysts' assessment points toward 'Revenues- BD Life Sciences- Biosciences- International' reaching $251.12 million. The estimate points to a change of +2.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- BD Interventional- Peripheral Intervention- United States' will likely reach $278.49 million. The estimate indicates a change of +3.9% from the prior-year quarter.
The consensus estimate for 'Revenues- BD Interventional- Urology and Critical Care- United States' stands at $307.52 million. The estimate points to a change of +10.2% from the year-ago quarter.
Analysts predict that the 'Revenues- BD Interventional- United States' will reach $863.64 million. The estimate suggests a change of +4.6% year over year.
Analysts expect 'Revenues- BD Interventional- Surgery- International' to come in at $92.84 million. The estimate indicates a change of +6.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- BD Interventional- Peripheral Intervention- International' will reach $216.57 million. The estimate indicates a year-over-year change of +1.2%.
The consensus among analysts is that 'Revenues- BD Interventional- Urology and Critical Care- International' will reach $78.47 million. The estimate suggests a change of +3.2% year over year.
Becton Dickinson shares have witnessed a change of -1.3% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #2 (Buy), BDX is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Becton Dickinson (BDX) Q4: Wall Street Projections for Key Metrics
The upcoming report from Becton Dickinson (BDX - Free Report) is expected to reveal quarterly earnings of $3.77 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $5.35 billion, representing an increase of 5.2% year over year.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Becton Dickinson metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- BD Medical' should come in at $2.73 billion. The estimate indicates a change of +7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional' of $1.25 billion. The estimate points to a change of +51.7% from the year-ago quarter.
Analysts forecast 'Revenues- BD Life Sciences' to reach $1.37 billion. The estimate suggests a change of +2.7% year over year.
The average prediction of analysts places 'Revenues- BD Life Sciences- Biosciences' at $408.06 million. The estimate indicates a year-over-year change of +0.8%.
Based on the collective assessment of analysts, 'Revenues- BD Medical- Medication Management Solutions- International' should arrive at $191.71 million. The estimate suggests a change of -1.2% year over year.
Analysts' assessment points toward 'Revenues- BD Life Sciences- Biosciences- International' reaching $251.12 million. The estimate points to a change of +2.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- BD Interventional- Peripheral Intervention- United States' will likely reach $278.49 million. The estimate indicates a change of +3.9% from the prior-year quarter.
The consensus estimate for 'Revenues- BD Interventional- Urology and Critical Care- United States' stands at $307.52 million. The estimate points to a change of +10.2% from the year-ago quarter.
Analysts predict that the 'Revenues- BD Interventional- United States' will reach $863.64 million. The estimate suggests a change of +4.6% year over year.
Analysts expect 'Revenues- BD Interventional- Surgery- International' to come in at $92.84 million. The estimate indicates a change of +6.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- BD Interventional- Peripheral Intervention- International' will reach $216.57 million. The estimate indicates a year-over-year change of +1.2%.
The consensus among analysts is that 'Revenues- BD Interventional- Urology and Critical Care- International' will reach $78.47 million. The estimate suggests a change of +3.2% year over year.
View all Key Company Metrics for Becton Dickinson here>>>
Becton Dickinson shares have witnessed a change of -1.3% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #2 (Buy), BDX is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>